Prostate Cancer Daily
November 29, 2021
Videos
Peer-to-Peer Clinical Conversations
Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio
Ana Aparicio
In this UroToday discussion Alicia Morgans and Ana Aparicio, discuss androgen indifferent prostate cancer and how to define those patients.
View
A Trial of VERU-100 for the Treatment of Advanced Prostate Cancer – Ronald Tutrone
Ronald Tutrone
Alica Morgans is joined by Ronald Tutrone to provide an update on the clinical trial VERU 100.
View
Beyond the Abstracts
MRI-Derived PRECISE Scores for Predicting Pathologically-Confirmed Radiological Progression in Prostate Cancer Patients on Active Surveillance - Beyond the Abstract
Impact of Surgical Wait Times During Summer Months on the Oncological Outcomes Following Robotic-Assisted Radical Prostatectomy: 10 Years' Experience from a Large Canadian Academic Center - Beyond the Abstract
Conference Coverage
SIU 2021: The Future of Prostate Cancer Imaging: Will AI Play a Role?
ASTRO 2021: 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation Therapy in Localized Prostate Cancer
ASTRO 2021: A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) Prior to Radical Prostatectomy in Locally Advanced Prostate Cancer
ASTRO 2021: Performance of a Genomic Classifier Within a Phase 3 Randomized Trial of Dose Escalated Salvage Radiotherapy After Radical Prostatectomy
Articles
Prostate Cancer
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations.
Multiphoton Microscopy for Identifying Collagen Signatures Associated with Biochemical Recurrence in Prostate Cancer Patients.
A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease.
Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy.
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.
CONNECT WITH US
Questions or Comments? Email us at
editors@urotoday.com
Digital Science Press, Inc.
548 Market Street #41552
San Francisco, CA 94104-5401
You are receiving this email because you have chosen to receive emails from UroToday.
Add us to your address book
View this email as a web page
Forward to a colleague
Manage your subscriptions
Unsubscribe
Copyright ©2021 Digital Science Press, Inc.
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free